BioMarin to Attend Upcoming Investor Conferences
August 31, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
Citi’s 11th Annual Biotech Conference September 7 in Boston Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York Leerink Partners...
Forbes Ranks BioMarin 10th Most Innovative Company in the World
August 24, 2016 09:53 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 24, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that it has been ranked 10th on Forbes magazine's 2016 list of the "World's Most...
BioMarin Announces Pricing of Public Offering of Common Stock
August 09, 2016 09:00 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today the pricing of an underwritten public offering of 7,500,000 shares of its common...
BioMarin Announces Public Offering of Common Stock
August 08, 2016 16:32 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today an offering, subject to market and other conditions, of 7,500,000 shares of its...
BioMarin Announces Second Quarter 2016 Financial Results
August 04, 2016 16:03 ET
|
BioMarin Pharmaceutical Inc.
- Second Quarter 2016 Total BioMarin Revenue Increases 20.0% Y/Y to $300.1 million- Vimizim Net Product Revenue Increases 98.1% Y/Y and Contributes $106.8 million in the Second Quarter 2016; Vimizim...
FDA Accepts BLA for BioMarin’s Cerliponase Alfa for CLN2 Disease, Form of Batten Disease
July 27, 2016 18:01 ET
|
BioMarin Pharmaceutical Inc.
Potential First Treatment for Fatal, Rare, Brain Disease in ChildrenFDA Grants Priority Review Status and Breakthrough Therapy DesignationPDUFA Action Date is January 27, 2017MAA Submitted to European...
BioMarin Provides Positive Proof-of-Concept Data for BMN 270 Gene Therapy in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress
July 27, 2016 14:30 ET
|
BioMarin Pharmaceutical Inc.
6 of 7 High Dose Patients Show Factor VIII levels above 50%, 7th patient above 10% No Clinically Relevant Sustained Rises in ALT Phase 2b Study to Begin Mid-2017 for Potential Accelerated Approval...
BioMarin to Provide Updated Data for BMN 270 in Hemophilia A in Late Breaking Oral Presentation at the World Federation of Hemophilia (WFH) 2016 World Congress July 27th
July 21, 2016 16:03 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 21, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that interim results of an open-label, Phase 1/2 study of BMN 270, an AAV5-FVIII Gene...
BioMarin Appoints Two BioPharmaceutical Veterans to Board of Directors, Willard Dere, M.D. and Kathryn E. Falberg
July 18, 2016 08:31 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic diseases, today announced the appointment of...
BioMarin to Host Second Quarter 2016 Financial Results Conference Call and Webcast on Thursday, August 4 at 4:30pm ET
July 14, 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., July 14, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...